NCT06314529招募中不适用
Long-term Follow-up Study of BHC001 in the Treatment of Transfusion-dependent β-thalassemia
Bioray Laboratories2 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2022年12月14日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 6
- 试验地点
- 2
- 主要终点
- Frequency, grade, and relationship of SAEs
研究概览
简要总结
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
详细描述
Observe long-term delayed safety risks such as emerging neoplasms, emerging haematological disorders, and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 5 Years 至 35 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
- •Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.
排除标准
- •There are no exclusion criteria for this study
结局指标
主要结局
Frequency, grade, and relationship of SAEs
时间窗: Within 2 years to 5years after BRL-101 Infusion
Frequency, grade, and relationship to BRL-101 of SAEs following BRL-101 reinfusion
Incidence of hematologic malignancies
时间窗: Up to 15 years post-drug product infusion
Such as new lymphoma, leukemia, MDS, etc.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Long-term Follow-up Study of BRL-101 for TDTThalassemia, BetaNCT06298630Bioray Laboratories45
已完成
3 期
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary IncontinenceUrinary IncontinenceOveractive BladderNCT00915525Allergan829
已完成
3 期
Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)Chronic Low Back PainChronic Regional Pain SyndromeChronic Soft Tissue PainRheumatoid ArthritisOsteoarthritisNCT00613106Amgen179
Enrolling By Invitation
3 期
A Long-term Follow-up Study in Participants Who Received CTX001Beta-ThalassemiaHematologic DiseasesHemoglobinopathiesGenetic Diseases, InbornSickle Cell AnemiaSickle Cell DiseaseThalassemiaNCT04208529Vertex Pharmaceuticals Incorporated160
撤回
不适用
Long-Term Follow-up of the Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles TendinosisTendinosisTendinopathyNCT02655042RepliCel Life Sciences, Inc.